Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 30

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 and activities related to regulatory filings
for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily
consist of:

●clinical
trial and regulatory-related costs;

21

    ●
    expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;

    ●
    manufacturing and testing costs and related supplies and materials; and

    ●
    employee-related expenses, including salaries, benefits, travel and stock-based compensation.

The following table summarizes
our research and development expenses by product candidate for the periods indicated (in thousands):

    Three Months Ended 

    March 31, 

    2025  
    2024 
  
    External Costs 

    DN-TNF - Alzheimer’s disease 
    $4,852  
    $6,354 
  
    INKmune – (High Risk MDS/AML & Prostate cancer) and CORDStrom 
     1,273  
     1,187 
  
    Preclinical and other programs 
     -  
     113 
  
    Accrued research and development rebate 
     (93) 
     (309)
  
    Total external costs 
     6,032  
     7,345 
  
    Internal costs 
     1,607  
     1,348 
  
    Total 
    $7,639  
    $8,693 

We typically use our employee
resources across our development programs. We track outsourced development costs by product candidate or development program, but we do
not allocate internal costs personnel costs including salaries and stock-based compensation to specific product candidates or development
programs.

We
participate, through our wholly owned subsidiary in Australia, in the Australian research and development tax incentive program, such
that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives
are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. 

We
participate, through our wholly owned subsidiary in the United Kingdom, in the research and development program provided by the United
Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United
Kingdom government, and such incentives are